[1] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis[J]. J Hepatol, 2015, 63(4): 971-1004. DOI: 10.1016/j.jhep.2015.06.030.
|
[2] |
TAUBERT R, JAECKEL E. Autoimmunhepatitis-Standard- und Zweitlinientherapie [Autoimmune hepatitis-standard and second-line therapy][J]. Internist (Berl), 2018, 59(6): 536-543. DOI: 10.1007/s00108-018-0434-1.
|
[3] |
PUUSTINEN L, BOYD S, MUSTONEN H, et al. Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis[J]. Scand J Gastroenterol, 2017, 52(3): 321-327. DOI: 10.1080/00365521.2016.1253768.
|
[4] |
∅RSTAVIK KH. Why are autoimmune diseases more prevalent in women?[J]. Tidsskr Nor Laegeforen, 2017, 137(12-13): 866-868. DOI: 10.4045/tidsskr.16.0935.
|
[5] |
LIBERT C, DEJAGER L, PINHEIRO I. The X chromosome in immune functions: When a chromosome makes the difference[J]. Nat Rev Immunol, 2010, 10(8): 594-604. DOI: 10.1038/nri2815.
|
[6] |
MOULTON VR. Sex hormones in acquired Immunity and autoimmune disease[J]. Front Immunol, 2018, 9: 2279. DOI: 10.3389/fimmu.2018.02279.
|
[7] |
RIBBONS KA, MCELDUFF P, BOZ C, et al. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS[J]. PLoS One, 2015, 10(6): e0122686. DOI: 10.1371/journal.pone.0122686.
|
[8] |
ABDULKARIM M, ZENOUZI R, SEBODE M, et al. Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis[J]. Scand J Gastroenterol, 2019, 54(11): 1391-1396. DOI: 10.1080/00365521.2019.1683226.
|
[9] |
LUCEY MR, NEUBERGER JM, WILLIAMS R. Primary biliary cirrhosis in men[J]. Gut, 1986, 27(11): 1373-1376. DOI: 10.1136/gut.27.11.1373.
|
[10] |
SAYINER M, GOLABI P, STEPANOVA M, et al. Primary biliary cholangitis in medicare population: The impact on mortality and resource use[J]. Hepatology, 2019, 69(1): 237-244. DOI: 10.1002/hep.30174.
|
[11] |
SHAHARIR SS, KADIR WDA, NORDIN F, et al. Systemic lupus erythematosus among male patients in Malaysia: How are we different from other geographical regions?[J]. Lupus, 2019, 28(1): 137-144. DOI: 10.1177/0961203318812676.
|
[12] |
AL-CHALABI T, UNDERHILL JA, PORTMANN BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis[J]. J Hepatol, 2008, 48(1): 140-147. DOI: 10.1016/j.jhep.2007.08.013.
|
[13] |
MONTANO-LOZA AJ, CARPENTER HA, CZAJA AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis[J]. Am J Gastroenterol, 2008, 103(8): 1944-1951. DOI: 10.1111/j.1572-0241.2008.01922.x.
|
[14] |
DONET JA, PERLINI EF, GILINSKY D, et al. Impact of gender on clinical presentation, response to treatment, and long-term outcomes in an ethnically diverse population of patients with autoimmune hepatitis[J]. J Hepatol, 2016, 64(2): s439. http://www.researchgate.net/publication/308577254_Impact_of_Gender_on_Clinical_Presentation_Response_to_Treatment_and_Long-Term_Outcomes_in_an_Ethnically_Diverse_Population_of_Patients_with_Autoimmune_Hepatitis
|
[15] |
HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
|
[16] |
ALVAREZ F, BERG PA, BIANCHI FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
|
[17] |
WEILER-NORMANN C, SCHRAMM C. Drug induced liver injury and its relationship to autoimmune hepatitis[J]. J Hepatol, 2011, 55(4): 747-749. DOI: 10.1016/j.jhep.2011.02.024.
|
[18] |
YEONG TT, LIM KH, GOUBET S, et al. Natural history and outcomes in drug-induced autoimmune hepatitis[J]. Hepatol Res, 2016, 46(3): e79-e88. DOI: 10.1111/hepr.12532.
|
[19] |
CHAZOUILLÈRES O, WENDUM D, SERFATY L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy[J]. Hepatology, 1998, 28(2): 296-301. DOI: 10.1002/hep.510280203.
|
[20] |
BOBERG KM, CHAPMAN RW, HIRSCHFIELD GM, et al. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. DOI: 10.1016/j.jhep.2010.09.002.
|
[21] |
FUKUI H, SAITO H, UENO Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol, 2016, 51(7): 629-650. DOI: 10.1007/s00535-016-1216-y.
|
[22] |
GRR∅NBAK L, VILSTRUP H, JEPSEN P. Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study[J]. J Hepatol, 2014, 60(3): 612-617. DOI: 10.1016/j.jhep.2013.10.020.
|
[23] |
XUE M, SHEN Y, SHEN MY, et al. Autoimmune hepatitis-related autoantibodies and their clinical significance[J]. J Clin Hepatol, 2019, 35(6): 1392-1396. DOI: 10.3969/j.issn.1001-5256.2019.06.048.
雪梅, 沈怡, 沈梦益, 等. 自身免疫性肝炎相关自身抗体及临床意义[J]. 临床肝胆病杂志, 2019, 35(6): 1392-1396. DOI: 10.3969/j.issn.1001-5256.2019.06.048.
|
[24] |
ZHANG WC, ZHAO FR, CHEN J, et al. Meta-analysis: Diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis[J]. PLoS One, 2014, 9(3): e92267. DOI: 10.1371/journal.pone.0092267.
|
[25] |
CZAJA AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis[J]. J Hepatol, 1999, 30(3): 394-401. DOI: 10.1016/s0168-8278(99)80096-8.
|
[26] |
DINSER R, BRAUN A, JENDRO MC, et al. Increased titres of anti-nuclear antibodies do not predict the development of associated disease in the absence of initial suggestive signs and symptoms[J]. Scand J Rheumatol, 2007, 36(6): 448-451. DOI: 10.1080/03009740701406577.
|
[27] |
VALGEIRSSON KB, HREINSSON JP, BJÖRNSSON ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs[J]. Liver Int, 2019, 39(12): 2341-2349. DOI: 10.1111/liv.14224.
|
[28] |
FLOREANI A, DE MARTIN S, SECCHI MF, et al. Extrahepatic autoimmunity in autoimmune liver disease[J]. Eur J Intern Med, 2019, 59: 1-7. DOI: 10.1016/j.ejim.2018.10.014.
|
[29] |
MURATORI P, FABBRI A, LALANNE C, et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease[J]. Eur J Gastroenterol Hepatol, 2015, 27(10): 1175-1179. DOI: 10.1097/MEG.0000000000000424.
|
[30] |
WONG GW, YEONG T, LAWRENCE D, et al. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: Implications for diagnosis, clinical course and long-term outcomes[J]. Liver Int, 2017, 37(3): 449-457. DOI: 10.1111/liv.13236.
|
[31] |
GOWER E, ESTES C, BLACH S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(1 Suppl): S45-S57. DOI: 10.1016/j.jhep.2014.07.027.
|
[32] |
REZAEE ZAVAREH MS, ALAVIAN SM, KARIMISARI H, et al. Occult hepatitis C virus infection in patients with autoimmune hepatitis[J]. Hepat Mon, 2014, 14(8): e16089. DOI: 10.5812/hepatmon.16089.
|
[33] |
MENG J. Epidemiological survey of hepatitis B virus infection in hospitals: A cross-sectional study[D]. Changchun: Jilin University, 2016.
孟静. 乙型肝炎病毒感染医院流行病学调查: 一项横断面研究y[D]. 长春: 吉林大学, 2016.
|
[34] |
TAUBERT R, DIESTELHORST J, JUNGE N, et al. Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis[J]. Sci Rep, 2018, 8(1): 17452. DOI: 10.1038/s41598-018-35882-7.
|
[35] |
PARKER R, OO YH, ADAMS DH. Management of patients with difficult autoimmune hepatitis[J]. Therap Adv Gastroenterol, 2012, 5(6): 421-437. DOI: 10.1177/1756283X12450251.
|
[36] |
TANSEL A, KATZ LH, EL-SERAG HB, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217.e4. DOI: 10.1016/j.cgh.2017.02.006.
|